LongeVC portfolio company Rubedo Life Sciences has announced a new strategic partnership with SVAX during the Future Investment Initiative (FII9) and Global Health Exhibition (GHE25) in Riyadh. The collaboration will enable Rubedo to conduct clinical trials for its lead program, RLS-1496, in Saudi Arabia and the UAE.
Supported by Hevolution Foundation, Fakeeh Care Group, and M42 Health, the partnership marks an important milestone in establishing the Middle East as an emerging hub for longevity and biotech research. Rubedo’s first-in-class selective GPX4 modulator will be evaluated for atopic dermatitis, a condition that affects up to 30% of adults in Saudi Arabia and is linked to age-related changes in skin biology.
Read the full announcement here.
Supported by Hevolution Foundation, Fakeeh Care Group, and M42 Health, the partnership marks an important milestone in establishing the Middle East as an emerging hub for longevity and biotech research. Rubedo’s first-in-class selective GPX4 modulator will be evaluated for atopic dermatitis, a condition that affects up to 30% of adults in Saudi Arabia and is linked to age-related changes in skin biology.
Read the full announcement here.